RecruitingPhase 1NCT07433569

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

Phase I Study to Compare the Pharmacokinetics of Budesonide and Formoterol Delivered With Symbicort Aerosphere® and Symbicort® pMDI in Children 4 to Less Than 12 Years of Age With Asthma

Sponsor

AstraZeneca

Enrollment

12 participants

Start Date

Mar 5, 2026

Study Type

INTERVENTIONAL

Conditions

Asthma

Summary

The purpose of this study is to assess the pharmacokinetics (PK) and safety of symbicort aerosphere and symbicort pressurized metered dose inhaler (pMDI) in participants with asthma aged 4 to less than 12 years.

Eligibility

Min Age: 4 YearsMax Age: 12 Years

Inclusion Criteria9

Participants who have clinician-diagnosed asthma for at least 3 months.
Body mass index ≤ 95 percentile for age and body weight of at least 15 kg or higher.
Be on a stable dose of one of the following asthma treatments for at least 4 weeks prior to screening (Visit 1):
Short-acting β2 agonist (SABA) used as rescue/reliever medication (as needed) only.
Low- or medium-dose inhaled corticosteroids (ICS).
Leukotriene receptor antagonist (LTRA).
Low-dose ICS/long-acting β2-agonist (LABA).
Medium-dose ICS/LABA.
Female participants who experience menarche must have a negative urine pregnancy test at screening.

Exclusion Criteria10

Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other severe respiratory abnormalities other than asthma.
History of life-threatening asthma defined as any asthma episode associated with loss of consciousness, intubation or admission to an intensive care unit.
History of severe asthma exacerbation within 8 weeks of Visit 1.
Inability to change from any budesonide therapy to another suitable corticosteroid.
Participants with a known hypersensitivity to budesonide and/or formoterol fumarate or any of the excipients of the product.
Not be able to refrain from consuming alcohol and smoking (including electronic cigarettes, vaping, and marijuana) from the time of screening until after the safety follow-up visit.
Unstable asthma.
Received regular maintenance treatment with prohibited anti-inflammatory or long-acting bronchodilator asthma medication.
Evidence of active liver disease.
Prolonged QT interval corrected for heart rate using Fridericia's correction (QTcF).